You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新世界(600628.SH):蔡同德藥業擬出資400萬元對上海徐重道中藥飲片增資擴股
格隆匯 08-31 16:22

格隆匯8月31日丨新世界(600628.SH)公佈,公司全資子公司上海蔡同德藥業有限公司(“蔡同德藥業”或“乙方”),於2021年8月30日在上海同上海藥房股份有限公司(“甲方”)、上海徐重道中藥飲片有限公司(“丙方”)三方共同簽署了《上海徐重道中藥飲片有限公司增資擴股協議》

次增資擴股前,丙方系甲方於2021年6月3日依法出資註冊成立的全資子公司,公司註冊資本為人民幣100萬元,甲方持有丙方100%股權。

次增資擴股價格以丙方經審計評估確認的現有淨資產人民幣100.005萬元為依據,蔡同德藥業擬以自有資金現金人民幣400.02萬元的投資金額認繳丙方新增的人民幣400萬元註冊資本,投資金額超過註冊資本的溢價部分200元計入丙方資本公積。

次增資擴股完成後,丙方註冊資本由原來的100萬元增加至人民幣500萬元,各方的持股比例分別為:甲方出資人民幣100萬元,持有丙方20%的股份;蔡同德藥業出資人民幣400萬元,持有丙方80%的股份。

次增資擴股事項完成後,蔡同德藥業持有丙方上海徐重道中藥飲片有限公司80%股權,可與蔡同德藥業實現資源整合、優勢互補、協同發展的作用,有利於更好的推進新世界“大健康”產業做強做大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account